Clinical Trial

Anti-inflammatory Therapy for Recurrent In-stent Restenosis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study is aimed at making a comparison of the safety and efficacy of standard drug therapy (control group), standard drugs combined with lose-dose colchicine therapy (colchicine group) and standard drug combined with prednisone therapy (prednisone group) in patients with coronary heart disease who suffered from recurrent In-stent restenosis (RISR).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-15; most recent amendment 2025-08-05.
Status change: Not Yet Recruiting → Recruiting 2024-09-24
Trial Details
NCT Number NCT06090890
Lead Sponsor Fu Wai Hospital, Beijing, China
Conditions In-stent Restenosis
Enrollment 252 participants
Start Date 2023-10-30
Primary Completion 2026-10-29 (estimated)
Study Completion 2027-10-29 (estimated)
Updated on ClinicalTrials.gov 2025-08-08